Request Demo

Last update 08 May 2025

Retinal Drusen

Last update 08 May 2025

Basic Info

Synonyms

Colloid bodies in retina, DRUSEN BODY, Degenerative drusen of retina

+ [25]

Introduction

Colloid or hyaline bodies lying beneath the retinal pigment epithelium. They may occur either secondary to changes in the choroid that affect the pigment epithelium or as an autosomal dominant disorder of the retinal pigment epithelium.

Drugs associated with Retinal Drusen

Curcumin

Target

DNMT1 x MDM2 x Nrf2 x RBM3 x TGF-β x TLR4 x VEGF

Mechanism

DNMT1 inhibitors [+6]

Active Org.

Nova Southeastern University, Inc. [+43]

Originator Org.

The University of Texas MD Anderson Cancer Center

Active Indication

Inflammation [+37]

Inactive Indication

Adenocarcinoma [+3]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Retinal Drusen

ISRCTN10005321

/ RecruitingNot ApplicableIIT

early Detection Of neovascular age-Related mAcular Degeneration in the cOmmunity

Start Date06 Jun 2024

Sponsor / Collaborator

The University of York

NCT06860555

/ CompletedNot Applicable

Exploration of the Retinal Deep PhenotypingTM (RDP) Platform for the Identification of Spatial-spectral Features in Different Types of Drusenoid Deposits in Dry Age-related Macular Degeneration (AMD)

This observational, cross-sectional study is designed to explore the feasibility to extract spatial-spectral features from hyperspectral retinal images captured with Optina Diagnostics' MHRC that are characteristic to the different types of drusenoid deposits associated with dry age-related macular degeneration.

Start Date08 Nov 2022

Sponsor / Collaborator

Optina Diagnostics, Inc.

NCT05056025

/ Unknown statusNot Applicable

A PILOT STUDY TO EVALUATE THE PROGRESSION OF THE DISEASE AND RESPONSE TO SUPPLEMENTATION WITH POSTBIOTICS IGEN-0222 IN PATIENTS WITH MACULAR DEGENERATION

A pilot study to establish the efficacy and safety of supplementation with postbiotics in patients with macular degeneration.

Start Date02 Dec 2020

Sponsor / Collaborator

Institut de la Màcula i la Retina SL

[+1]

100 Clinical Results associated with Retinal Drusen

100 Translational Medicine associated with Retinal Drusen

0 Patents (Medical) associated with Retinal Drusen

143

Literatures (Medical) associated with Retinal Drusen

01 May 2025·Ophthalmology Science

Validation of Deep Learning–Based Automatic Retinal Layer Segmentation Algorithms for Age-Related Macular Degeneration with 2 Spectral-Domain OCT Devices

Article

Author: Chew, Emily ; Duic, Cameron ; De Silva, Tharindu ; Cukras, Catherine ; Jayakar, Gopal ; Keenan, Tiarnan D L ; Thavikulwat, Alisa T ; Mukherjee, Souvick

PurposeSegmentations of retinal layers in spectral-domain OCT (SD-OCT) images serve as a crucial tool for identifying and analyzing the progression of various retinal diseases, encompassing a broad spectrum of abnormalities associated with age-related macular degeneration (AMD). The training of deep learning algorithms necessitates well-defined ground truth labels, validated by experts, to delineate boundaries accurately. However, this resource-intensive process has constrained the widespread application of such algorithms across diverse OCT devices. This work validates deep learning image segmentation models across multiple OCT devices by testing robustness in generating clinically relevant metrics.DesignProspective comparative study.ParticipantsAdults >50 years of age with no AMD to advanced AMD, as defined in the Age-Related Eye Disease Study, in ≥1 eye, were enrolled. Four hundred two SD-OCT scans were used in this study.MethodsWe evaluate 2 separate state-of-the-art segmentation algorithms through a training process using images obtained from 1 OCT device (Heidelberg-Spectralis) and subsequent testing using images acquired from 2 OCT devices (Heidelberg-Spectralis and Zeiss-Cirrus). This assessment is performed on a dataset that encompasses a range of retinal pathologies, spanning from disease-free conditions to severe forms of AMD, with a focus on evaluating the device independence of the algorithms.Main Outcome MeasuresPerformance metrics (including mean squared error, mean absolute error [MAE], and Dice coefficients) for the segmentations of the internal limiting membrane (ILM), retinal pigment epithelium (RPE), and RPE to Bruch's membrane region, along with en face thickness maps, volumetric estimations (in mm³). Violin plots and Bland-Altman plots comparing predictions against ground truth are also presented.ResultsThe UNet and DeepLabv3, trained on Spectralis B-scans, demonstrate clinically useful outcomes when applied to Cirrus test B-scans. Review of the Cirrus test data by 2 independent annotators revealed that the aggregated MAE in pixels for ILM was 1.82 ± 0.24 (equivalent to 7.0 ± 0.9 μm) and for RPE was 2.46 ± 0.66 (9.5 ± 2.6 μm). Additionally, the Dice similarity coefficient for the RPE drusen complex region, comparing predictions to ground truth, reached 0.87 ± 0.01.ConclusionsIn the pursuit of task-specific goals such as retinal layer segmentation, a segmentation network has the capacity to acquire domain-independent features from a large training dataset. This enables the utilization of the network to execute tasks in domains where ground truth is hard to generate.Financial DisclosuresProprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

01 Oct 2024·Canadian Journal of Ophthalmology

Risk of ocular adverse events with aromatase inhibitors

Article

Author: Liu, Victoria ; Lo, Cody ; Etminan, Mahyar ; Maberley, David ; Feng, Zhao Xun ; Sriranganathan, Aswen

OBJECTIVEAromatase inhibitors (AIs) are a class of medications used for adjuvant treatment of breast cancer. Recent case reports suggest that AIs may be associated with various ocular adverse events (AEs). This study evaluates the risk of ocular AEs in patients who take AIs.METHODDisproportionality analysis was performed using data from the U.S. Food and Drug Administration's Adverse Events Reporting System database from 2004 to 2022. All cases of vitreomacular traction, macular edema, retinal deposits, retinal artery occlusion, macular hole, retinal hemorrhage, uveitis, retinal tear, retinal detachment, dry eye disease, blepharitis, and optic neuropathy were searched for the 3 AIs anastrozole, letrozole, and exemestane. A search also was performed on trastuzumab as a control. Reported odds ratios (RORs) and corresponding 95% CIs were computed.RESULTSWe identified 322 ocular AEs of interest for the 3 AIs and 55 for trastuzumab. Anastrozole had the most AEs (n = 163) and was found to have strong associations with vitreomacular traction (ROR = 665; 95% CI, 352-1255), macular edema (ROR = 37; 95% CI, 25-54), retinal deposits (ROR = 11; 95% CI, 2-77), and uveitis (ROR = 6; 95% CI, 4-9). Letrozole had strong associations with retinal deposits (ROR = 8, 95% CI, 1-57) and retinal artery occlusion (ROR = 6; 95% CI, 3-11). Exemestane had a strong association with macular holes (ROR = 10; 95% CI, 3-30).CONCLUSIONDisproportionality analysis revealed an increased risk of ocular AEs with each of the AIs. This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities.

30 Apr 2024·Investigative Ophthalmology & Visual Science

Spatially Resolved Association of Structural Biomarkers on Retinal Function in Non-Exudative Age-Related Macular Degeneration Over 4 Years

Article

Author: Schmitz-Valckenberg, Steffen ; von der Emde, Leon ; Holz, Frank G. ; Saßmannshausen, Marlene ; Vaisband, Marc ; Hasenauer, Jan ; Ach, Thomas ; Döngelci, Senem ; Sloan, Kenneth R.

PurposeTo longitudinally assess the impact of high-risk structural biomarkers for natural disease progression in non-exudative age-related macular degeneration (AMD) on spatially resolved mesopic and scotopic fundus-controlled perimetry testing.MethodsMultimodal retinal imaging data and fundus-controlled perimetry stimuli points were semiautomatically registered according to landmark correspondences at each annual visit over a period of up to 4 years. The presence of sub-RPE drusen, subretinal drusenoid deposits, pigment epithelium detachments (PEDs), hyper-reflective foci (HRF), vitelliform lesions, refractile deposits, and incomplete RPE and outer retinal atrophy (iRORA) and complete RPE and outer retinal atrophy (cRORA) were graded at each stimulus position and visit. Localized retinal layer thicknesses were extracted. Mixed-effect models were used for structure-function correlation.ResultsFifty-four eyes of 49 patients with non-exudative AMD (mean age, 70.7 ± 9.1 years) and 27 eyes of 27 healthy controls (mean age, 63.4 ± 8.9 years) were included. During study course, presence of PED had the highest functional impact with a mean estimated loss of -1.30 dB (P < 0.001) for mesopic and -1.23 dB (P < 0.001) for scotopic testing, followed by HRF with -0.89 dB (mesopic, P = 0.001) and -0.87 dB (scotopic, P = 0.005). Subretinal drusenoid deposits were associated with a stronger visual impairment (mesopic, -0.38 dB; P = 0.128; scotopic, -0.37 dB; P = 0.172) compared with sub-RPE drusen (-0.22 dB, P = 0.0004; -0.18 dB, P = 0.006). With development of c-RORA, scotopic retinal sensitivity further significantly decreased (-2.15 dB; P = 0.02). Thickening of the RPE-drusen-complex and thinning of the outer nuclear layer negatively impacted spatially resolved retinal sensitivity.ConclusionsThe presence of PED and HRF had the greatest prognostic impact on progressive point-wise sensitivity losses. Higher predominant rod than cone-mediated localized retinal sensitivity losses with early signs of retinal atrophy development indicate photoreceptor preservation as a potential therapeutic target for future interventional AMD trials.

News (Medical) associated with Retinal Drusen

31 May 2022

·www.biospace.com

AffaMed Therapeutics Announces First Patient Dosed in the US Phase 1 Clinical Trial of AM712 in Retinal Disease

SHANGHAI, May 30, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, announces that the first patient has been dosed in its US Phase 1 study of AM712 (ASKG712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) for the treatment of retinal diseases. The study will investigate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in subjects with neovascular age-related macular degeneration (nAMD). Dr. Dayao Zhao, CEO of AffaMed commented: "Dosing the first patient with AM712 is another example of the AffaMed team's effective execution and global clinical development expertise. Initiating treatment in retinal disease patients marks an important milestone for AffaMed, and we look forward to advancing AM712 as an innovative and differentiated therapy for the patient population with nAMD and other retinal diseases." Age-related macular degeneration (AMD) is an acquired degeneration of the retina that results in significant central vision loss due to neovascular (choroidal neovascular membrane formation) and non-neovascular (drusen and retinal pigment epithelium abnormalities) damages. Neovascular AMD is an advanced form of macular degeneration that has historically been the leading cause of AMD-related vision loss. Simultaneous neutralization of VEGF and Ang-2 represents a novel therapeutic approach to treat nAMD with better efficacy. In late 2021, AffaMed entered into a licensing agreement with AskGene Pharma Inc. ("AskGene") for the exclusive rights to develop, manufacture, and commercialize AM712 globally in ex-Asia plus Japan territories. Soon after, the Investigational New Drug (IND) application, filed by AffaMed for the clinical development of AM712 was cleared by the United States Food and Drug Administration (FDA) in January 2022. About AffaMed Therapeutics AffaMed Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders for patients in Greater China and around the world. The leadership team at AffaMed Therapeutics has gained deep industry expertise and an extensive track record in high-quality discovery, clinical development, regulatory affairs, business development, manufacturing, and commercial operations at leading multi-national biopharmaceutical companies in China and globally. About AM712 (ASKG712) AM712 is a novel bispecific biologic molecule specifically designed for ocular use. It provides dual inhibition of two important disease-relevant pathways in retinal diseases, VEGF and Ang-2. In pre-clinical studies, AM712 demonstrated robust efficacy, good ocular pharmacokinetics, and the desired safety pro clinical exploration. AskGene received China CTA clearance for AM712 from NMPA in January 2022.

Collaborate

Analysis

Perform a panoramic analysis of this field.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis